AstraZeneca PLC (AZN)vsOrganon & Co (OGN)
AZN
AstraZeneca PLC
$185.95
+1.10%
HEALTHCARE · Cap: $282.69B
OGN
Organon & Co
$13.40
-0.30%
HEALTHCARE · Cap: $3.53B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 881% more annual revenue ($60.44B vs $6.16B). AZN leads profitability with a 17.2% profit margin vs 4.0%. OGN trades at a lower P/E of 14.4x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
OGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Margin of Safety
+38.3%
Fair Value
$12.46
Current Price
$13.40
$0.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Every $100 of equity generates 34 in profit
Earnings expanding 66.7% YoY
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Distress zone — elevated risk
4.0% margin — thin
Weak financial health signals
Revenue declined 3.5%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : OGN
The strongest argument for OGN centers on Return on Equity, EPS Growth, P/E Ratio.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : OGN
The primary concerns for OGN are Profit Margin, Piotroski F-Score, Revenue Growth. Debt-to-equity of 9.49 is elevated, increasing financial risk. Thin 4.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while OGN is a value play — different risk/reward profiles.
OGN carries more volatility with a beta of 1.54 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 58/100), backed by strong 17.2% margins and 12.5% revenue growth. OGN offers better value entry with a 38.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Organon & Co
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?